Blood and endothelial cells: together through thick and thin

Area of Science:

• Hematology
• Oncology
• Cell Biology

Background:

• Myelofibrosis (MF) is a chronic myeloproliferative neoplasm characterized by bone marrow fibrosis.
• The JAK2V617F mutation is a common driver mutation in myelofibrosis, primarily found in hematopoietic stem cells.
• The cellular origins and distribution of this mutation in MF are not fully understood.

Purpose of the Study:

• To investigate the presence and distribution of the JAK2V617F mutation in non-hematopoietic cells within the spleen of myelofibrosis patients.
• To determine if endothelial cells (ECs) in MF patients harbor the JAK2V617F mutation.

Main Methods:

• Analysis of spleen tissue and splenic vein samples from patients diagnosed with JAK2V617F-positive myelofibrosis.
• Utilizing sensitive molecular techniques to detect the JAK2V617F mutation in isolated endothelial cells.

Main Results:

• The JAK2V617F mutation was detected in a subset of endothelial cells (ECs) isolated from spleen tissues.
• The mutation was also identified in ECs from the splenic vein of these patients.
• This indicates the mutation's presence in the vascular endothelium within the spleen.

Conclusions:

• The JAK2V617F mutation is not exclusive to hematopoietic cells in myelofibrosis and can be found in endothelial cells of the spleen.
• This finding suggests a broader cellular involvement of the mutation in the pathogenesis of myelofibrosis.
• Further research is warranted to understand the implications of EC mutation for MF progression and potential therapeutic strategies.